The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
A partnering deal with J&J worth $300m in upfront cash, over a largely ignored second pipeline candidate, should put the Belgian biotech firmly on the map.
Promising mid-stage data in a third indication for efgartigimod have given the Belgian company another boost.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.